Novartis AG (NVS)
NYSE: NVS · IEX Real-Time Price · USD
102.84
+0.27 (0.26%)
May 20, 2024, 4:00 PM EDT - Market closed
Novartis AG Revenue
Novartis AG had revenue of $49.92B in the twelve months ending March 31, 2024, with 8.81% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $12.12B with 9.71% year-over-year growth. In the year 2023, Novartis AG had annual revenue of $46.66B with 7.36% growth.
Revenue (ttm)
$49.92B
Revenue Growth
+8.81%
P/S Ratio
4.02
Revenue / Employee
$656,402
Employees
76,057
Market Cap
201.21B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
Dec 31, 2005 | 29.75B | 2.48B | 9.08% |
Dec 31, 2004 | 27.28B | 2.35B | 9.41% |
Dec 31, 2003 | 24.93B | 4.05B | 19.41% |
Dec 31, 2002 | 20.88B | 2.12B | 11.27% |
Dec 31, 2001 | 18.76B | -3.07B | -14.06% |
Dec 31, 2000 | 21.83B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
Pfizer | 55.09B |
AbbVie | 54.40B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Amgen | 29.53B |
NVS News
- 4 days ago - Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash - GlobeNewsWire
- 5 days ago - Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA - GlobeNewsWire
- 13 days ago - Cagent Vascular appoints Chairman Brian Walsh to expanded role as Chief Executive Officer - Business Wire
- 18 days ago - Novartis to buy radiology specialist Mariana Oncology for $1 billion - Reuters
- 18 days ago - Novartis to pay up to $1.75 billion for U.S. cancer-focused biotech - Market Watch
- 18 days ago - Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer - Business Wire
- 20 days ago - PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis - Business Wire
- 21 days ago - Morphosys says Novartis takeover progressing as planned for H1 2024 - Reuters